| Merus Announces the Journal Publication of Petosemtamab Mechanism of Action |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. |
globenewswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Merus to Present at BofA Securities 2025 Health Care Conference |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. |
globenewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates |
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2025-05-07 23:40:40 |
Czytaj oryginał (ang.) |
| Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update |
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting |
globenewswire.com |
2025-05-07 20:11:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline |
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-07 15:05:50 |
Czytaj oryginał (ang.) |
| Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting |
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation |
globenewswire.com |
2025-04-23 14:00:00 |
Czytaj oryginał (ang.) |
| Merus: Riding The Bispecific Wave In Oncology |
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers. |
seekingalpha.com |
2025-04-07 08:34:07 |
Czytaj oryginał (ang.) |
| Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates |
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago. |
zacks.com |
2025-02-27 22:05:20 |
Czytaj oryginał (ang.) |
| Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update |
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 |
globenewswire.com |
2025-02-27 18:10:00 |
Czytaj oryginał (ang.) |
| Merus to Present at Upcoming Investor Conferences |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. |
globenewswire.com |
2025-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. |
globenewswire.com |
2025-02-05 19:00:00 |
Czytaj oryginał (ang.) |
| Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff |
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications. |
seekingalpha.com |
2025-01-20 07:08:49 |
Czytaj oryginał (ang.) |
| Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs |
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies. |
globenewswire.com |
2025-01-12 22:04:00 |
Czytaj oryginał (ang.) |
| Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5. |
globenewswire.com |
2024-12-16 18:01:00 |
Czytaj oryginał (ang.) |
| Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC |
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 |
globenewswire.com |
2024-12-07 03:30:00 |
Czytaj oryginał (ang.) |
| Merus Scores Its First FDA Approval For Lung Cancer Drug |
On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. |
benzinga.com |
2024-12-05 16:49:30 |
Czytaj oryginał (ang.) |
| Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI® has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction.1 See Important Safety Information below. |
globenewswire.com |
2024-12-04 18:55:00 |
Czytaj oryginał (ang.) |
| Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) and Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, today announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the United States (U.S.). |
globenewswire.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 |
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC |
globenewswire.com |
2024-12-01 13:05:00 |
Czytaj oryginał (ang.) |
| Biotech Stock Boosted on Brand-New 'Buy' Rating |
Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating. |
schaeffersresearch.com |
2024-11-21 12:48:35 |
Czytaj oryginał (ang.) |
| Merus to Present at Upcoming Investor Conferences |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: |
globenewswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Merus: Petosemtamab Set Up For December 2024 Data Presentation |
Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono Pharmaceutical, funding operations into 2028. |
seekingalpha.com |
2024-11-05 15:18:14 |
Czytaj oryginał (ang.) |
| Merus Receives FDA extension of PDUFA for zenocutuzumab |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for zenocutuzumab (Zeno) Biologics License Application (BLA) currently under priority review. |
globenewswire.com |
2024-11-05 08:30:00 |
Czytaj oryginał (ang.) |
| Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates |
Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. |
zacks.com |
2024-10-31 12:26:14 |
Czytaj oryginał (ang.) |
| Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update. |
globenewswire.com |
2024-10-31 10:08:00 |
Czytaj oryginał (ang.) |
| Merus: Great European Oncology Developer, But Properly Valued |
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success. |
seekingalpha.com |
2024-08-14 21:13:14 |
Czytaj oryginał (ang.) |
| Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates |
Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago. |
zacks.com |
2024-08-01 22:31:31 |
Czytaj oryginał (ang.) |
| Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update |
– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients |
globenewswire.com |
2024-08-01 20:10:00 |
Czytaj oryginał (ang.) |
| Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-29 15:06:25 |
Czytaj oryginał (ang.) |
| Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC |
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback |
globenewswire.com |
2024-07-24 11:00:00 |
Czytaj oryginał (ang.) |
| Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. |
globenewswire.com |
2024-06-03 18:30:00 |
Czytaj oryginał (ang.) |
| Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. |
globenewswire.com |
2024-06-02 16:30:00 |
Czytaj oryginał (ang.) |
| Merus Announces Pricing of Upsized Public Offering of Common Shares |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $400.2 million. All of the shares in the offering are to be sold by Merus. |
globenewswire.com |
2024-05-30 01:30:00 |
Czytaj oryginał (ang.) |